

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU BIOPHARMA CO., LTD.
樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2157)

**CLOSURE OF REGISTER OF MEMBERS FOR
THE 2024 FIRST AND SECOND EXTRAORDINARY
GENERAL MEETINGS TO BE HELD ON JANUARY 31, 2024**

References are made to the announcement of Lepu Biopharma Co., Ltd. (the “**Company**”) dated November 13, 2023, in relation to, among other things, the CDMO Services Framework Agreement that the Company conditionally entered into on even date, and to the announcement of the Company dated December 22, 2023, in relation to, among other things, the Supplemental CDMO Services Framework Agreement that the Company conditionally entered into on even date and the Proposed Revised Cap stipulated thereunder (collectively, the “**Announcements**”). Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

The Company will convene the 2024 first extraordinary general meeting of the Company (the “**2024 First EGM**”), which is scheduled to be held on Wednesday, January 31, 2024, for the purpose of considering and, if thought fit, approving the CDMO Services Framework Agreement (as supplemented by the Supplemental CDMO Services Framework Agreement) (including the Proposed Revised Cap) and the transactions contemplated thereunder. The Company will convene the 2024 second extraordinary general meeting of the Company (the “**2024 Second EGM**”), which is scheduled to be held on Wednesday, January 31, 2024 immediately after the conclusion of the 2024 First EGM. The Board hereby announces that, for the purpose of determining the identity of the shareholders of the Company (the “**Shareholders**”) who are entitled to attend and vote at the 2024 First EGM and the 2024 Second EGM, the register of members of the Company will be closed from Friday, January 26, 2024 to Wednesday, January 31, 2024, both days inclusive. The Shareholders whose names appear on the register of members of the Company on Wednesday, January 31, 2024 will be entitled to attend and vote at the 2024 First EGM and the 2024 Second EGM. During such period, no share transfers will be registered. In order to be eligible for attending and voting at the 2024 First EGM and the 2024 Second EGM, all properly completed transfer documents accompanied by the relevant share certificates must be lodged for registration with the Company’s H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Thursday, January 25, 2024.

The circulars containing details of the resolutions to be proposed at the 2024 First EGM and the 2024 Second EGM, together with notices of the 2024 First EGM and the 2024 Second EGM and the corresponding proxy forms, will be despatched to the Shareholders in due course.

By order of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC
January 11, 2024

As at the date of this announcement, the Board comprises Dr. Pu Zhongjie (chairman), Dr. Sui Ziye (chief executive officer) and Dr. Hu Chaohong (co-chief executive officer) as executive Directors; Ms. Pu Jue, Mr. Yang Hongbing and Mr. Lin Xianghong as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.